GlassScriptPhysician profile
Lisa Davis
NPI 1972809416
$5,808.33
in general payments reported to CMS, 2019-2025
38 companies · $943 in 2025
The $943 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $910 · 2023: $2,883 · 2024: $643 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,356 · Travel and Lodging: $2,014 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.82 |
| Travel and Lodging | $2,013.79 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $2,593.57 | 2022-2023 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $479.68 | 2021-2025 | Breztri, Tezspire, Fasenra |
| Novo Nordisk INC | $385.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $210.76 | 2021-2025 | Trelegy Ellipta, Nucala |
| Zealand Pharma US, INC. | $184.76 | 2021 | |
| Jazz Pharmaceuticals INC. | $168.93 | 2021-2024 | |
| Lilly USA, LLC | $146.81 | 2022-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $132.26 | 2023-2025 | Sunosi |
| Amgen INC. | $126.25 | 2022-2025 | Tezspire |
| Inspire Medical Systems, INC. | $120.17 | 2023-2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $117.01 | 2024-2025 | Cuvitru, Hyqvia, Glassia |
| Harmony Biosciences LLC | $99.99 | 2024 | |
| Novartis Pharmaceuticals Corporation | $96.78 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $84.95 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.80 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $82.81 | 2021 | |
| Abbott Laboratories | $81.92 | 2022 | |
| Emd Serono, INC. | $79.86 | 2022 | |
| Grifols USA, LLC | $71.63 | 2025 | Xembify |
| Genzyme Corporation | $60.53 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $54.57 | 2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $36.62 | 2022-2023 | Uptravi, Opsumit |
| Azurity Pharmaceuticals, INC. | $27.30 | 2025 | Alvesco |
| Pfizer INC. | $27.09 | 2022 | |
| Atricure, INC. | $25.58 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Corcept Therapeutics | $23.83 | 2025 | Korlym |
| Ionis Pharmaceuticals, INC. | $21.87 | 2025 | Tryngolza |
| Exact Sciences Corporation | $21.32 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $18.41 | 2025 | Zoryve |
| Genentech USA, INC. | $18.37 | 2023 | Xolair |
| Eisai INC. | $18.00 | 2021 | |
| Electromed, INC. | $17.79 | 2022 | |
| Resmed Corp | $17.50 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $16.93 | 2024 | Lumryz |
| Csl Behring | $15.29 | 2025 | Hizentra |
| Optinose US, INC. | $14.51 | 2025 | |
| Insmed, INC. | $13.37 | 2023 | Arikayce |
| Sandoz INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.